Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by Stifel Financial Corp

Stifel Financial Corp grew its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 115.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 20,354 shares of the medical equipment provider’s stock after acquiring an additional 10,924 shares during the quarter. Stifel Financial Corp’s holdings in Hologic were worth $1,658,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Quantinno Capital Management LP raised its holdings in Hologic by 10.9% in the third quarter. Quantinno Capital Management LP now owns 41,424 shares of the medical equipment provider’s stock valued at $3,374,000 after buying an additional 4,063 shares during the period. Quarry LP raised its stake in shares of Hologic by 88.7% in the 3rd quarter. Quarry LP now owns 3,413 shares of the medical equipment provider’s stock valued at $278,000 after acquiring an additional 1,604 shares during the period. Royal London Asset Management Ltd. lifted its holdings in shares of Hologic by 6.0% during the 3rd quarter. Royal London Asset Management Ltd. now owns 335,011 shares of the medical equipment provider’s stock valued at $27,290,000 after acquiring an additional 19,095 shares in the last quarter. Janus Henderson Group PLC boosted its position in Hologic by 2.9% during the 3rd quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock worth $2,344,000 after purchasing an additional 800 shares during the period. Finally, HighTower Advisors LLC increased its holdings in Hologic by 9.8% in the 3rd quarter. HighTower Advisors LLC now owns 22,603 shares of the medical equipment provider’s stock valued at $1,832,000 after purchasing an additional 2,012 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

HOLX has been the topic of a number of recent research reports. BNP Paribas upgraded Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Needham & Company LLC restated a “buy” rating and issued a $90.00 price target on shares of Hologic in a report on Thursday. Royal Bank of Canada increased their price objective on shares of Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. Mizuho reduced their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Finally, Raymond James raised their price target on shares of Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Six research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Hologic presently has a consensus rating of “Moderate Buy” and a consensus target price of $89.50.

Hologic Stock Up 1.3 %

Shares of Hologic stock opened at $71.65 on Friday. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The business has a 50-day moving average price of $78.65 and a 200 day moving average price of $78.52. Hologic, Inc. has a fifty-two week low of $70.36 and a fifty-two week high of $84.67. The firm has a market cap of $16.26 billion, a P/E ratio of 21.52, a P/E/G ratio of 2.38 and a beta of 0.96.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.01. The business had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business’s revenue was up 4.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.89 EPS. On average, sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Transactions at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.75% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.